Experimental Alzheimer's drug shows modest cognitive decline delay, pending U.S. approval

A new experimental drug called lecanemab has shown it can slow the cognitive decline of Alzheimer's patients, at least modestly, offering the first real evidence that targeting the disease's underlying biology might actually work. The findings, published this week in The New England Journal of Medicine and presented at an Alzheimer's conference in San Francisco, come from a study of nearly 1,800 people aged 50 to 90 in the early stages of the disease. For eighteen months, half received lecanemab intravenously every two weeks, while the other half received a placebo infusion. The results are real but small: patients on the drug showed a cognitive decline that was less than half a point slower on an 18-point scale measuring mental and functional ability. Measured another way, the drug delayed disease progression by roughly five months over the study period. Thirty-one percent fewer patients on lecanemab advanced to the next stage of the disease during the trial.

The announcement comes from Eisai, a Japanese pharmaceutical company, and Biogen, its American partner, both of which have been waiting for this moment. After years of failed attempts to find treatments that actually work, the scientific community is energized. U.S. regulators could approve lecanemab as early as January. But the enthusiasm masks a deeper question: does any of this actually matter to the people living with Alzheimer's and the families caring for them?

Medical experts are divided on that point. Madhav Thambisetty, a researcher at the National Institute on Aging, said the difference reported in this study is unlikely to be noticeable to individual patients. Many researchers believe a clinically meaningful improvement would require at least a full point on that 18-point scale. Ron Petersen, an Alzheimer's specialist at the Mayo Clinic, takes a more optimistic view, calling the drug's effect "modest, but clinically significant." Maria Carrillo, the scientific director of the Alzheimer's Association, framed it differently: this is the first time anyone has shown that slowing Alzheimer's is even possible. She pointed out that even a few months of preserved cognitive function in early disease stages could mean the difference between recognizing family members, taking vacations, or checking items off a bucket list.

The drug works by attacking amyloid, a protein long suspected of driving Alzheimer's damage. Proving that an amyloid-targeting drug can actually slow disease progression is scientifically significant, even if the clinical benefit feels small. But lecanemab comes with real risks. About 13 percent of patients who received the drug experienced brain swelling, though Eisai says most cases were mild or caused no symptoms. More troubling, two deaths were reported among patients taking lecanemab who were also on anticoagulant medications. Eisai has said those deaths cannot be attributed to the Alzheimer's drug, but Petersen said that if lecanemab is approved, he will avoid prescribing it to patients on blood thinners, at least initially.

The approval process will likely move quickly. But the real test will come after that, when doctors and patients must decide whether a drug that delays decline by five months, with potential risks of brain bleeding, is worth the cost and the commitment of regular intravenous infusions. For some families, those extra months of preserved memory and function will feel like everything. For others, the modest gains and safety questions may not justify the burden.